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incidence
In 2006 the estimated age-adjusted annual incidence of breast
cancer in the European Union (25 countries) was 110.3/100 000
and the mortality 25.0/100 000. The incidence is increasing due
to mammographic screening and aging population. The
mortality rate has decreased especially in younger age groups
because of earlier detection and improved treatment. However,
breast cancer is still the leading cause of cancer-related deaths
in European women.
diagnosis
The diagnosis is based on the triad of clinical, radiological and
pathological examinations. Clinical examination includes bi-
manual palpation of the breasts and local regional lymph
nodes. Radiological examinations include bilateral
mammography of the breasts and ultrasound of the breasts and
local regional lymph nodes. MRI of the breasts is not a routine
procedure, but may be considered in cases involving diagnostic
challenges arising, for example, because of dense breast tissue or
positive axillary lymph node status with occult primary tumor
in the breast. Pathological diagnosis should be based on core
needle biopsy obtained by manual, or preferably by ultrasound
or stereotactic guidance. A core needle biopsy, or if that is not
possible, at least a fine needle aspiration indicating carcinoma
should be obtained before any surgical operations. Final
pathological diagnosis should be made according to the World
Health Organization (WHO) classification and the tumor–
node–metastases (TNM) staging system analyzing all tissue
removed.
staging and risk assessment
Patient-related staging examinations include complete personal
medical history, family history relating to breast/ovarian and
other cancers, physical examination, performance status, full
blood count, liver and renal function tests, alkaline phosphatase
and calcium. Assessing the menopausal status is imperative, if
in doubt, by measuring serum hormone levels.
Preoperative disease-related staging includes clinical TNM
staging, pathological examination of the core needle biopsy
with a pathologist’s report on histologic type and grade, and
providing there is sufficient tissue available, determination of
estrogen receptor (ER), progesterone receptor (PgR) and
HER2 receptor status by IHC or FISH/CISH test [III, B].
If preoperative (neoadjuvant) systemic therapy is planned,
additional investigations such as thorax X-ray, abdominal
ultrasound and bone scintigraphy should be considered to
exclude metastatic disease. These investigations are
recommended also for patients with clinically advanced disease
(clinically positive axillary nodes, large tumors) or with
laboratory values or clinical signs or symptoms indicating the
presence of metastases, even if preoperative systemic treatment
is not planned [III, B].
Postoperatively the pathologist’s report should include:
number of tumors in the tissue removed, the maximum
diameter of the largest tumor (T), histologic type and grade of
the tumor, evaluation of the resection margins including the
minimum margin in millimetres and its anatomical direction;
total number of removed lymph nodes, number of positive
lymph nodes, extent of metastases in the lymph nodes (ITC,
micrometastatic, metastatic), i.e. N-status. Performing sentinel
node biopsy is recommended in the surgical staging of the
axilla for patients with clinical stage I or stage II breast cancer.
The report should also include immunohistochemical
evaluation of ER and PgR using a standardized assessment
methodology, e.g. Allred or H score, and immunohistochemical
evaluation of HER2 receptor expression. HER2 gene
amplification status may be determined directly from all
tumors using in situ hybridization (FISH or CISH) or
only from tumors with an ambiguous (2+)
immunohistochemistry. Vascular and lymphovascular invasion
should also be reported.
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Risk stratification currently includes three categories: low,
intermediate and high risk, based on calculated risk of
recurrence involving age, tumor size, histopathological grade,
vascular invasion, axillary lymph node involvement, ER/PgR
status and HER2 status (Table 1).
The place of gene/molecular profiling shows promise but
requires prospective validation before routine use.
treatment plan
Multidisciplinary discussion involving an oncologist, breast
surgeon, radiologist, radiation oncologist and pathologist
leading to treatment planning should be used to integrate local
and systemic therapies and their sequence [III, B]. The
possibility of hereditary cancer should be explored and, if
needed, prophylactic procedures discussed following adequate
genetic counseling and testing of the patient [IV, D].
local therapy
non-invasive carcinoma
Intraductal carcinoma (ductal carcinoma in situ, DCIS) may be
treated with breast-conserving surgery (BCS) providing healthy
tissue margins can be reached. There is no general consensus on
what is regarded as a safe (negative) margin. However, margins
>10 mm are adequate and margins <1 mm are inadequate.
Adjuvant breast irradiation after BCS decreases the risk of local
recurrence but has no effect on survival [I, A]. This decrease in
risk of local recurrence is evident in all subtypes of DCIS.
However, in some patients with low-risk DCIS (tumor size
<10 mm, low/intermediate nuclear grade, adequate surgical
margins), the risk of local recurrence following excision only is
so low that omitting radiation may be an option. Especially in
ER-positive DCIS tamoxifen may be considered following BCS
(with or without adjuvant radiation) [II, A]. Total mastectomy
with clear margins in DCIS is curative, and radiation therapy is
not recommended. In this group of patients tamoxifen may
also be considered as a risk reduction therapy to decrease the
risk of contralateral breast cancer [II,B]. Lobular carcinoma in
situ (LCIS) is a risk factor for future development of invasive
cancer in both breasts (RR 5.4–12).
invasive carcinoma
Invasive breast cancer is operated by using BCS or mastectomy,
both combined with sentinel node biopsy (SNB) alone, SNB
followed by axillary dissection or axillary dissection without
SNB, depending on clinical situation. SNB should not be
performed in cases of palpable axillary node(s), in large
(>3 cm) T2–T4 tumors, multicentric tumors, prior axillary
surgery or large biopsies, after breast reconstruction or
implantation of a prosthesis, during pregnancy or lactation,
and after neoadjuvant systemic treatment outside clinical trials.
Contraindications to BCS include multicentric tumors, large
tumors (>3–4 cm) in small breasts especially when no neo-
adjuvant therapy is planned, positive margins after resection,
inflammatory breast cancer and patient’s own wish.
Postoperative radiotherapy is strongly recommended after BCS
[I, A]. Radiotherapy reduces the risk of local recurrence by two-
thirds and has a beneficial effect on survival. In patients >70
years of age who have receptor-positive invasive breast cancer
with maximum stage pT1N0 and clear postoperative margins it
may be possible to use adjuvant tamoxifen instead of radiation
therapy [II, B].
Table 1. Risk categories for patients with operated breast cancer
Low risk Node-negative and all of the following features Estimated risk of recurrence in 10 years (%)
pT £ 2 cm <10
Grade 1
Absence of extensive peritumoral vascular invasion
ER and/or PgR expressed
HER2 gene neither overexpressed nor amplified
Age ‡ 35 years
Intermediate risk Node-negative and at least one of the following features
pT > 2 cm 10–50
Grade 2–3
Presence of extensive peritumoral vascular invasion
ER and PgR absent
HER2 gene overexpressed or amplified
Age < 35 years OR
Node-positive (1–3 involved nodes) AND
ER and/or PgR expressed AND
HER2 gene neither overexpressed nor amplified
High risk Node-positive (1–3 involved nodes) AND
ER and PgR absent OR >50
HER2 gene overexpressed or amplified OR
Node-positive (4 or more involved nodes)
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Post-mastectomy radiotherapy is always recommended for
patients with four or more positive axillary nodes [II, B], and
indicated for patients with T3–T4 tumors independent of the
nodal status [III, B]. Post-mastectomy radiotherapy may also
be considered in cases of at least T1 tumor with 1–3 positive
axillary lymph nodes, particularly if young, and in cases of T2
or greater medially located tumors which show signs of
biological aggressiveness (receptor-negative, grade 3, HER2-
positive, high proliferation activity, e.g. Ki-67).
primary (neo-adjuvant) systemic
therapy
Primary systemic therapy is indicated for locally advanced
breast cancer (stages IIIA–B) including inflammatory breast
cancer [III, B] and for large operable tumors for reducing
tumor size in order to possibly perform BCS [I, A]. Before
primary systemic therapy a biopsy for histopathology and
analyses of predictive factors should be performed. In addition,
for these high-risk patients full clinical staging to rule out
metastatic disease is necessary. It may employ chemo- or
endocrine therapy based on predictive factors similar to
adjuvant treatment. Trastuzumab should be considered in the
treatment protocol in HER2-positive tumors. It should be
followed by both surgery and radiotherapy and postoperative
systemic adjuvant treatment.
adjuvant systemic therapy
Treatment is initiated providing that there is a relevant
reduction of (calculated) risk of recurrence which can be
reached with an acceptable level of treatment-related adverse
effects. Hormone receptor and HER2 status are the most
relevant predictive factors for the choice of treatment modality.
Tumors with an incomplete (some expression) or high degree
of expression of ER and/or PgR are considered endocrine
responsive. Patients with no detectable expression of ER and
PgR in their tumors are considered endocrine non-responsive.
Features indicative of uncertainty of endocrine responsiveness
include low levels of steroid hormone receptor
immunoreactivity, lack of PgR, G3, high proliferation markers
(Ki-67), HER2 overexpression and possibly uPA and PAI-1.
Patients with tumors considered endocrine responsive may
receive endocrine treatment alone (Table 2), or a combination
of endocrine therapy and chemotherapy. Patients with tumors
of uncertain endocrine responsiveness are usually treated with
a combination of endocrine therapy and chemotherapy.
Patients with endocrine non-responsive tumors derive greater
benefit from chemotherapy and should not receive endocrine
therapy. In addition to endocrine and chemotherapy, patients
with HER2 overexpression or amplification should be
considered for adjuvant treatment with trastuzumab (see
below). For each individual, the choice of adjuvant therapy
must take into account the potential benefits, possible side-
effects and patient preference. Several decision-making tools
have been developed to help doctor–patient communication
for adjuvant treatment decisions.
endocrine therapy
Patients with tumors considered uncertainly or highly
endocrine responsive should be treated with endocrine therapy
(Table 2).
In premenopausal patients tamoxifen alone (20 mg daily for
5 years) or the combination of ovarian function ablation with
tamoxifen are standard therapies. Ovarian function ablation
may be achieved by bilateral oophorectomy which leads to
irreversible ablation of ovarian function. Gonadotropin-
releasing hormone analogues (GnRHAs) generally lead to
reversible ovarian suppression sufficient for therapeutic
activity. GnRHAs should be given for at least 2 years, although
optimal duration for this treatment has not been established
[III, D]. Combining GnRHAs and aromatase inhibitors (AIs) in
premenopausal patients is not indicated, as is the use of AIs
alone. In premenopausal patients GnRHAs may be started
concurrently with chemotherapy, leading to rapid amenorrhea.
In postmenopausal patients 5 years of tamoxifen alone is still
a viable option for certain patient categories. For the use of AIs
a switch from tamoxifen to an AI after 2–3 years of tamoxifen
or initial use of an AI for 5 years are most commonly accepted
strategies [I, A]. Initial use of an AI is the preferred option in
patients at higher risk of relapse (large tumor size, node
positivity, HER2-positive disease). For patients who have
completed 5 years of tamoxifen the addition of an AI for
a further period of 2–3 years may be recommended in cases
with node-positive disease [I, A]. The total duration of optimal
adjuvant endocrine treatment is between 5 and 10 years, 5 years
for tamoxifen alone being standard. Sequential rather than
concurrent administration of cytotoxic and endocrine therapies
should be used [II, A]. It is unclear whether AIs should be
started concurrently with chemotherapy (CT + ET) or
sequentially after chemotherapy (CT/ET).
The long-term skeletal adverse effects associated with AIs are
an issue of concern. Women treated with AIs should receive
Table 2. Choice of treatment modalities according to St Gallen Consensus 2007 (Goldhirsch A et al., 2007)
HER2 status Highly endocrine responsive Incompletely endocrine responsive Endocrine non-responsive
Negative ETa (consider adding CT according to risk)b ETa (consider adding CT according to risk)b CT
Positive ET + Trastuzumab + CT ET + Trastuzumab + CT Trastuzumab + CT
aEndocrine therapy is effective for prevention and ductal carcinoma in situ and therefore might be considered even for very low-risk invasive breast cancer.
bWithin the highly and incompletely endocrine-responsive categories, addition of chemotherapy may be based on degree of steroid hormone receptor
expression and level of risk.
ET, endocrine therapy; CT, chemotherapy.
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vitamin D and calcium supplements. There is no clear evidence
for the concomitant use of bisphosphonates with AI in the
adjuvant setting. However, several randomized controlled trials
are ongoing with pending final results. Before commencing AI
treatment, women should have BMD assessed by DEXA with
a low threshold, and receive bisphosphonate if T-score is less
than 22,5 SD, which equals to osteoporosis.
chemotherapy
Adjuvant chemotherapy is generally recommended for
intermediate- or high-risk patients. A multiplicity of
chemotherapy regimens acceptable for adjuvant treatment exist
(Table 3). The use of anthracyclines for all patients and
especially for patients with HER2-positive disease may be
recommended. However, for some patients (elderly, cardiac
contraindication, etc.) non-anthracycline-containing regimes
(CMF) may still be appropriate [I, A]. The optimal duration of
the treatment is not known. However, at least four cycles (12–
16 weeks) should be administered, generally aiming for six to
eight cycles (18–24 weeks). The use of taxanes may be limited
to high-risk patients. The use of dose-dense schedules with
prophylactic G-CSF is controversial, whilst high-dose therapy
requiring peripheral blood stem cell support cannot be
recommended at all. A shorter duration of chemotherapy (12–
16 weeks) may be suitable for elderly patients, for whom the
role of chemotherapy remains uncertain. Premenopausal
women may benefit from 3- to 6-monthly bisphosphonate
infusions during the first year to prevent bone loss associated
with temporary or permanent hormonal changes during
adjuvant chemotherapy [II, B].
trastuzumab
Patients with HER2 receptor IHC overexpression (3+) or HER2
gene amplification benefit from adjuvant treatment with
trastuzumab. There are no relevant data to support the use of
trastuzumab as a standard treatment in women with a primary
tumor <1 cm in size and with no axillary node involvement,
especially in endocrine-responsive disease. Based on
pharmacokinetic analyses a 3-weekly schedule (6 mg/kg) is
considered equivalent to a weekly schedule (2 mg/kg). The
standard duration of adjuvant trastuzumab has not yet been
established but for the time being 1 year is recommended.
Trastuzumab may be started in parallel with a taxane, but it
should not be given concurrently with an anthracycline. Even
when given after an anthracycline-containing regimen
trastuzumab may have cardiotoxic effects and cardiac function
should be routinely monitored. To administer trastuzumab
with endocrine therapy without chemotherapy is not supported
by clinical trial evidence. It is important to avoid trastuzumab
in patients with low left ventricular ejection fraction (LVEF)
(<50%).
follow-up
There is no evidence from randomized trials supporting any
particular follow-up sequence or protocol. The aims of follow-
up are to find early possible local recurrences or contralateral
breast cancer, to evaluate possible treatment-related
complications (such as menopausal symptoms and
osteoporosis) and to treat them, and to provide psychological
support and information in order to enhance returning to
normal life after breast cancer. Whatever the follow-up
protocol and the frequency of visits, every visit should include
history taking, eliciting of symptoms and physical examination.
Ipsilateral (after BCS) and contralateral clinical mammography
is recommended yearly for premenopausal women and every 1–
2 years for postmenopausal women [D]. There are no data to
indicate that performing blood counts, chemistry, chest X-ray,
bone scan, liver ultrasound, CT scans of chest and abdomen or
any tumor markers such as CA 15-3 or CEA on asymptomatic
patients produces a survival benefit [I, A].
A DEXA scan should be performed for women experiencing
a premature menopause (<45 years of age), those on an AI
with a baseline T score of less than –1 SD and repeated every
2 years.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are given
in square brackets. Statements without grading were considered
justified standard clinical practice by the experts and the ESMO
faculty.
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